这篇小型综述总结了关于经口内镜下肌切开术治疗III型门失弛缓症的最新文献。强调在此过程中对定制肌切开术长度的科学知之甚少。此外,将特别关注当前的主观和客观生物标志物，比如Eckardt的分数,用于评估该人群的治疗结果，以更好地将现有的患者结果数据进行情境化，正如Low等人在本期杂志中提出的那样。了解III型门失弛缓症的当前治疗情况并确定研究缺陷的关键领域将指导该疾病的未来调查和管理。
This mini-review summarizes the most recent literature regarding per-oral endoscopic myotomy for type III achalasia, emphasizing the poorly understood science of tailoring myotomy length during this procedure. In addition, special attention will be placed on the current subjective and objective biomarkers, such as the Eckardt score, used to evaluate treatment outcomes in this population to better contextualize the existing data on patient outcomes, as proposed by Low et al in the current issue of the Journal. Understanding the current treatment landscape for type III achalasia and identifying the key areas of research deficiencies will guide future investigation and management of this disease.
